Infliximab shortage — IT supply status & alternatives

Infliximab

—

🇦🇺 AUST R 73827 · Janssen-Cilag Pty Ltd

In shortage · Australia

INFLECTRA infliximab

In declared shortage · 🇦🇺 Australia & also short in🇮🇹 IT

Critical shortage

Product discontinued / no longer available on the Australian market.

Reading today’s signals…

🇦🇺 AUAEMPA$186.16details →

• Can I substitute?

No pathway on record

prescriber decision required

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Active ingredient (INN)	Infliximab
Brand names	INFLECTRA infliximab
Therapeutic category	Auto-created by Therapeutic Goods Administration — Medicine Shortages scraper
Controlled substance	No
Marketing-authorisation holders	Janssen-Cilag Pty Ltd, Pfizer Australia Pty Ltd, Samsung Bioepis AU Pty Ltd, Janssen Biotech, Inc.
Registrations on file	7
Patient information leaflet (PIL)	Not on file
Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 PBS · July 2026

🇦🇺 AU

● Official price on file

Ex-manufacturer

A$186.16

AEMP

Dispensed (DPMQ)

—

incl. fees

Pack

infliximab 100 mg injection, 1 vial

Source: PBSEffective July 2026 · AUD

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders7 registrations · 4 MA holders

Product	Strength	Form	Market	MA holder	Status
REMICADE infliximab	100mg	—	🇦🇺 AU	Janssen-Cilag Pty Ltd	Active
JAXIMAB infliximab	100mg	—	🇦🇺 AU	Janssen-Cilag Pty Ltd	Active
INFLECTRA infliximab	100mg	—	🇦🇺 AU	Pfizer Australia Pty Ltd	Active
REMSIMA infliximab	100mg	—	🇦🇺 AU	—	Active
RENFLEXIS infliximab	100 mg	—	🇦🇺 AU	Samsung Bioepis AU Pty Ltd	Active
REMSIMA infliximab	120 mg	—	🇦🇺 AU	—	Active
INFLIXIMAB	100mg/10mL	injection	🇺🇸 US	Janssen Biotech, Inc.	Active

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.